IDEAYA Biosciences Files 8-K Report
Ticker: IDYA · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
IDEAYA filed an 8-K, likely covering an 'Other Event'. Details TBD.
AI Summary
On September 23, 2024, IDEAYA Biosciences, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events are detailed in the provided excerpt.
Why It Matters
This filing signals that IDEAYA Biosciences, Inc. has made a disclosure to the SEC, which could pertain to any material event not covered by other standard 8-K items.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications presented in the excerpt.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
FAQ
What specific 'Other Event' is IDEAYA Biosciences, Inc. reporting in this 8-K filing?
The provided excerpt does not specify the nature of the 'Other Event' being reported; it only indicates that this is the item of disclosure.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported in this 8-K filing is dated September 23, 2024.
What is IDEAYA Biosciences, Inc.'s principal executive office address?
IDEAYA Biosciences, Inc.'s principal executive offices are located at 5000 Shoreline Court, Suite 300, South San Francisco, California 94080.
What is IDEAYA Biosciences, Inc.'s telephone number?
IDEAYA Biosciences, Inc.'s telephone number is (650) 443-6209.
Under which section of the Securities Exchange Act of 1934 is this 8-K filing made?
This 8-K filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,461 words · 6 min read · ~5 pages · Grade level 16.2 · Accepted 2024-09-23 06:12:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- d884691d8k.htm (8-K) — 30KB
- 0001193125-24-223230.txt ( ) — 151KB
- idya-20240923.xsd (EX-101.SCH) — 2KB
- idya-20240923_lab.xml (EX-101.LAB) — 18KB
- idya-20240923_pre.xml (EX-101.PRE) — 11KB
- d884691d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain statements contained herein are forward-looking statements, including, but not limited to, statements related to (i) the timing of FDA regulatory guidance and a potential registration-enabling Phase 3 randomized clinical trial in neoadjuvant UM patients, (ii) the potential therapeutic benefits of the Company's therapeutics, (iii) the translation of preliminary clinical trial results into future clinical trial results, and (iv) the estimate of patient populations. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: September 23, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer